title: Angiotensin II and III microinjections into the zona incerta influence drinking behavior.
abstract: Different doses of angiotensin II (AII) or angiotensin III (AIII) microinjections into the zona incerta have been studied on drinking of rats in separate experiments during the consequent 60-min-daily-drinking period. Also, the dipsogen power of only the effective dose of AII and AIII was compared to vehicle treated rats. After, angiotensin receptor (AT(1), AT(2)) antagonists on AII or AIII induced drinking were tested. In the first and second experiments only the 100 ng AII and the 200 ng AIII increased water intake significantly. In the third experiment the AII started its dipsogen effect earlier, at the 5 min measuring time, compared to the AIII. Both effects kept on lasting parallel from the 10 min on. Considering the antagonist pre-treatments in the fourth experiment, animals were injected with 90 ng losartan, an AT(1) antagonist, 180 ng PD 123319 or 200 ng CGP 42112, both AT(2) antagonists, respectively. Both AII and AIII increased water consumption. The effect of AII could be blocked by losartan, but not by PD 123319 or CGP 42112. On the other hand, the effect of AIII could not be blocked by losartan, but by both the PD 123319 and CGP 42112. Since, the effects of AII, AIII and angiotensin antagonists have not been tested in the zona incerta, the finding that water intake increased after AII or AIII injections and it could be blocked only by either of the antagonists suggests that AT(1) and AT(2) receptors play partially different roles in the regulation of water intake.
authors.affiliation: Institute of Physiology and Neurophysiology Research Group of the Hungarian Academy of Sciences, Pécs University Medical School, Szigeti Street 12, H-7624 Pécs, Hungary.
authors.forename: Eva Eszter
authors.initials: EE
authors.lastname: Bagi
authors.forename: Eva
authors.initials: E
authors.lastname: Fekete
authors.forename: László
authors.initials: L
authors.lastname: Lénárd
mesh_terms: D000804:Angiotensin II / Q000494:pharmacology*; D000805:Angiotensin III / Q000494:pharmacology*; D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D004327:Drinking Behavior / Q000187:drug effects*; D004347:Drug Interactions; D007093:Imidazoles / Q000494:pharmacology; D019808:Losartan / Q000494:pharmacology; D008297:Male; D008845:Microinjections / Q000379:methods; D009842:Oligopeptides / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D020530:Subthalamus / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D007093:Imidazoles; D009842:Oligopeptides; D011725:Pyridines; D000804:Angiotensin II; D000805:Angiotensin III; C060894:CGP 42112A; C073402:PD 123319; D019808:Losartan